This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
IMPACT COPD is a completed study titled “Replication of the IMPACT COPD Trial in Healthcare Claims Data.” The registry lists COPD as the condition, two intervention arms, and an enrollment of 17281 participants. Its registered primary endpoint is the annual rate of moderate or severe COPD exacerbations during treatment, measured to study completion or censoring, up to 32 months.
| Feature | IMPACT COPD |
|---|---|
| ClinicalTrials.gov identifier | NCT05062304 |
| Acronym | IMPACT COPD |
| Study title | Replication of the IMPACT COPD Trial in Healthcare Claims Data |
| Status | COMPLETED |
| Condition | COPD |
| Enrollment | 17281 |
| Number of arms | 2 |
| Start date | 2020-12-13 |
| Primary completion date | 2021-07-22 |
| Lead sponsor | Brigham and Women's Hospital |
| Sponsor type | OTHER |
2. Clinical Question
The registry describes a replication of the IMPACT COPD trial using healthcare claims data. The principal statistical question is whether the two listed treatment groups differ in the annual rate of moderate or severe COPD exacerbations during treatment.
Population
The study enrolled 17281 participants in a study concerning COPD and healthcare claims data.
Intervention group 1
Fluticasone Furoate-Vilanterol Trifenatate.
Intervention group 2
Furoate-umeclidinium-vilanterol.
Primary question
How does the annual rate of moderate or severe COPD exacerbations during treatment compare between the two intervention groups?
3. Trial Design
The study title identifies the project as a replication of the IMPACT COPD trial in healthcare claims data. The registry lists two arms and the two drug interventions, but the ClinicalTrials.gov record does not specify a randomization ratio, blinding structure, allocation mechanism, stratification factors, or other design features.
Fluticasone Furoate-Vilanterol Trifenatate
- Intervention listed in the registry as a drug.
- Evaluated within the healthcare-claims replication study.
Furoate-umeclidinium-vilanterol
- Intervention listed in the registry as a drug.
- Evaluated within the healthcare-claims replication study.
4. Study Timeline
Study start
The registry lists 2020-12-13 as the study start date.
Primary completion
The registry lists 2021-07-22 as the primary completion date.
Study status
The registry identifies the study status as COMPLETED.
5. Primary Endpoint
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Annual rate of moderate or severe COPD exacerbations during treatment | Claims-based algorithm: see attached protocol for full definition | To study completion or censoring, up to 32 months |
This is a rate endpoint rather than a simple binary endpoint. The analysis concerns the number of qualifying exacerbation events accumulated during treatment relative to the amount of time contributed by participants. That distinction matters because two groups can have similar proportions of participants with at least one event while having different numbers of recurrent events or different amounts of observed treatment time.
The annualized rate uses both event counts and follow-up time. The registry specifies a claims-based algorithm for identifying moderate or severe COPD exacerbations, with observation continuing to study completion or censoring, up to 32 months.
6. Planned Analysis
The registry's primary endpoint is the annual rate of moderate or severe COPD exacerbations during treatment. No statistical estimates, confidence intervals, or p-values are posted in the registry's statistical-analysis section.
For an endpoint of this type, the natural statistical framework is a count-rate model that accounts for unequal person-time across participants. A Poisson model is a basic starting point when event counts are modeled in relation to exposure time. In clinical and claims-based data, however, exacerbation counts can show greater variability than a Poisson model permits. A negative binomial model is therefore commonly considered when overdispersion is present.
Person-time is incorporated through an offset, allowing participants with different observation periods to contribute appropriately to the estimated rate. A treatment-group comparison can then be expressed as a rate ratio, comparing the estimated annual event rate in one group with that in the other.
Here, the logarithm of person-time acts as an offset. Exponentiating the treatment coefficient gives a rate ratio under the specified model.
No formal statistical analyses were posted to ClinicalTrials.gov for this primary endpoint.
7. Statistical Methodology
Event-rate analysis
An annual exacerbation rate summarizes recurrent events over observed time. Unlike a time-to-first-event analysis, a rate analysis can account for multiple qualifying events occurring during the observation period, provided that the endpoint definition and counting rules permit them.
Person-time and censoring
The registry specifies observation to study completion or censoring, up to 32 months. Censoring therefore determines how much observation time each participant contributes to the rate calculation. Participants who are observed for different lengths of time cannot be compared fairly using raw event counts alone.
Poisson regression
Poisson regression models event counts while using person-time as an exposure offset. Under the Poisson assumption, the variance of the event count is closely related to its mean. If the observed variability is substantially greater, standard Poisson inference can be too narrow.
Negative binomial regression
Negative binomial regression introduces an additional dispersion component and is frequently used for recurrent clinical events when event counts are overdispersed. For COPD exacerbation data, this framework can be useful when participants have heterogeneous underlying event rates.
Rate ratios
A rate ratio compares two estimated event rates. A rate ratio below 1 indicates a lower estimated event rate in the numerator group relative to the reference group; a rate ratio above 1 indicates a higher estimated rate. The rate ratio is not a probability, and it does not state what proportion of individual participants experienced an exacerbation.
For example, a hypothetical rate ratio of 0.80 would describe an estimated event rate that is 20% lower in Group A than Group B. This example is illustrative only and is not a reported IMPACT COPD result.
8. Statistical Methods Explained
Why is this endpoint a rate rather than a simple percentage?
A percentage such as “the proportion with at least one exacerbation” treats the first event as the main unit of analysis. The registered endpoint instead specifies an annual rate, which is suited to situations where the number of events and the amount of observed treatment time both matter.
Why does person-time matter?
Suppose two groups accumulated the same number of exacerbations but one group contributed substantially more observation time. The raw event counts would be identical, but the event rates would not be. An offset for person-time allows the analysis to compare event occurrence relative to the amount of time under observation.
Why might a negative binomial model be considered?
Poisson regression assumes a particular relationship between the mean and variance of event counts. Recurrent clinical events can exhibit overdispersion because participants differ in their underlying susceptibility to events. A negative binomial model allows additional variability beyond the basic Poisson structure.
What does a rate ratio mean?
A rate ratio is a relative comparison of event rates. A value below 1 means the estimated rate is lower in the numerator group; a value above 1 means it is higher. It should not be interpreted as the percentage of participants who avoided an exacerbation or as a relative risk for a single event.
What role does censoring play?
Censoring ends the period during which a participant contributes observable event time. The registry explicitly defines the endpoint time frame as continuing to study completion or censoring, up to 32 months. The statistical analysis therefore needs to account for unequal observation periods.
Why does the claims algorithm matter statistically?
The statistical model can only analyze events that the endpoint definition identifies. If the claims-based algorithm classifies an event incorrectly, that measurement error can affect the estimated rate and the comparison between groups. The registry therefore points to the protocol for the full claims-based definition.
9. Endpoint Measurement and Claims Data
The primary endpoint is explicitly defined using a claims-based algorithm. This makes endpoint ascertainment a central component of the statistical design. The event is not simply a value recorded as a conventional laboratory measurement or a directly observed clinical score; it is identified according to a claims-based classification rule.
Event identification
Moderate or severe COPD exacerbations are identified through a claims-based algorithm.
Repeated events
The annual-rate formulation is compatible with an analysis of event counts over observed treatment time.
Observation time
Follow-up continues to study completion or censoring, up to 32 months.
Protocol definition
The registry directs readers to the attached protocol for the full endpoint definition.
For claims-based research, the statistical interpretation should therefore consider two linked questions: how accurately the claims algorithm identifies the clinical event and how appropriately the statistical model compares the resulting event rates. A sophisticated count model cannot compensate for a poorly specified event definition.
10. Exposure Time, Censoring, and Recurrent Events
The phrase “during treatment” is important because the endpoint is defined over an observation period rather than at one fixed assessment time. Participants can contribute different amounts of follow-up before study completion or censoring.
| Statistical component | Role in the primary endpoint |
|---|---|
| Event count | Number of moderate or severe COPD exacerbations identified by the claims-based algorithm. |
| Person-time | Amount of observed treatment time contributing to the annualized rate. |
| Censoring | Ends observable follow-up for a participant. |
| Study completion | One endpoint-defined stopping point for observation. |
| Maximum time frame | Up to 32 months. |
| Rate comparison | Compares event occurrence relative to observation time between the two arms. |
This structure differs from a conventional binary endpoint. If the analysis instead collapsed each participant to “ever had an exacerbation” versus “never had an exacerbation,” information about repeated events and exposure time could be lost.
11. Interpretation of a Potential Rate Ratio
If an analysis of this endpoint produced a rate ratio below 1 for the first intervention relative to the second, the estimate would indicate a lower modeled annual exacerbation rate in the first group. The magnitude would describe the relative difference in rates, not the proportion of participants experiencing a benefit.
A rate ratio would not mean that every participant had the same reduction in exacerbation risk. It would also not be equivalent to a hazard ratio or to the probability of having at least one exacerbation.
A confidence interval around a rate ratio would quantify statistical uncertainty under the selected modeling framework. A narrow interval would indicate greater statistical precision than a wide interval, but neither type of interval would describe the range of effects experienced by individual participants.
If a formal hypothesis test were reported, its p-value would describe evidence against a specified null hypothesis under the model and assumptions. It would not tell the reader how large or clinically important the difference in annual exacerbation rates is. The rate ratio and its confidence interval provide the effect estimate and its precision.
12. Statistical Assumptions
Any formal recurrent-event rate analysis requires assumptions about event generation, observation time, and the relationship between the statistical model and the underlying data. These assumptions should be evaluated rather than treated as automatic consequences of the endpoint definition.
- Person-time specification: the exposure offset must correspond to the time during which the participant is appropriately at risk and observable for the endpoint.
- Event independence structure: repeated exacerbations within the same participant may be correlated, which can affect standard errors if the model does not adequately account for within-person dependence.
- Overdispersion: if event-count variability exceeds the Poisson assumption, a negative binomial or another dispersion-aware approach may be more appropriate.
- Censoring: informative differences in censoring between groups can affect the validity of a simple rate comparison.
- Endpoint classification: misclassification of claims-defined exacerbations can affect both event rates and comparative estimates.
- Model specification: covariates, interactions, dispersion assumptions, and variance estimation should be selected according to the study's prespecified statistical plan.
13. Missing Data and Imputation
The registry information does not specify a missing-data or imputation strategy for the primary endpoint. For a claims-based recurrent-event endpoint, missingness can arise in several forms, including incomplete observation time or gaps in available claims information. The appropriate approach depends on how those gaps arise and how they affect the definition of the at-risk period.
Importantly, missingness of covariates and missingness of event ascertainment are different statistical problems. Imputation methods commonly used for incomplete baseline covariates do not automatically solve incomplete observation of recurrent claims-based events.
14. Stratification and Covariate Adjustment
The registry information does not identify prespecified stratification factors or a covariate-adjustment set for the primary endpoint. In a claims-based comparison, adjustment variables can be important because treatment groups may differ in measured characteristics before the analysis.
Possible adjustment strategies in this type of study can include regression adjustment or other confounding-control methods, but the choice of variables and model should be determined from the study design and statistical analysis plan rather than selected after examining the observed endpoint results.
15. Multiplicity, Interim Analysis, and Bayesian Methods
The registry information does not report a multiplicity strategy, interim efficacy analysis, alpha-spending procedure, or Bayesian analysis for the primary endpoint.
| Design feature | Registry information | Statistical implication |
|---|---|---|
| Multiplicity | Not specified in the available registry information. | No multiplicity adjustment should be assumed. |
| Interim analysis | Not specified in the available registry information. | No interim alpha-spending procedure should be assumed. |
| Bayesian methods | Not specified in the available registry information. | No Bayesian posterior analysis should be assumed. |
| Stratification | Not specified in the available registry information. | No prespecified stratification factors should be assumed. |
16. Limitations
- No posted statistical estimates: the ClinicalTrials.gov record does not post statistical estimates, confidence intervals, or p-values for the registered primary endpoint.
- Claims-based measurement: the primary endpoint depends on a claims-based algorithm, and the registry directs readers to the attached protocol for the full definition.
- Recurrent-event structure: annual rates can contain information about multiple events, but the appropriate model must account for repeated observations and person-time.
- Censoring: participants can contribute different amounts of observable treatment time, making the handling of censoring important to the rate estimate.
- Confounding considerations: a healthcare-claims replication can involve differences between treatment groups that require careful design and adjustment if causal comparisons are intended.
- Unreported design details: the available registry information does not specify randomization, allocation ratio, blinding, stratification factors, missing-data methods, interim analyses, or Bayesian methods.
- Interpretation of rates: an annual event rate is not interchangeable with a risk, cumulative incidence, or time-to-first-event probability.
17. Why This Trial Matters Statistically
IMPACT COPD is a useful statistical teaching case because its primary endpoint shifts attention away from a simple one-time outcome and toward recurrent clinical events observed over varying amounts of time. That structure creates several important analytical questions.
| Concept | How it appears in IMPACT COPD |
|---|---|
| Claims-based endpoint | Moderate or severe COPD exacerbations are identified using a claims-based algorithm. |
| Recurrent events | The endpoint is expressed as an annual rate rather than a simple binary outcome. |
| Person-time | Annualization requires the amount of observable treatment time contributed by participants. |
| Censoring | Observation continues to study completion or censoring, up to 32 months. |
| Count regression | Poisson or negative binomial frameworks are natural candidates for recurrent event-rate analysis. |
| Rate ratio | A comparative effect measure can express the relative difference between annual event rates. |
| Overdispersion | Heterogeneity in recurrent event counts can make negative binomial modeling relevant. |
| Endpoint validity | The statistical comparison depends on the validity of the claims-based event classification. |
The study also illustrates why statistical analysis cannot be separated entirely from endpoint construction. A rate model may be mathematically appropriate while still producing a misleading scientific conclusion if the claims algorithm does not adequately represent the clinical event of interest.
18. What the Annual Rate Does — and Does Not — Mean
An annual exacerbation rate describes the frequency of qualifying events relative to observed treatment time. It combines event counts with the amount of time during which those events could be observed.
An annual rate is not the percentage of participants who experienced an exacerbation. A participant can contribute more than one event, and participants can contribute different amounts of observation time.
A rate ratio describes the relative difference between two event rates. The underlying annual rates describe the absolute frequency of events per unit of time. Both perspectives can be important when interpreting a recurrent-event endpoint.
19. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The registered endpoint is an annual rate of moderate or severe COPD exacerbations during treatment. Its analysis naturally requires attention to event counts, person-time, censoring, and the statistical distribution of recurrent events.
Clinical interpretation
The endpoint is intended to quantify the frequency of clinically relevant COPD exacerbation events during treatment. Interpretation depends on the claims-based definition used to identify those events and the comparative rate estimates produced by the analysis.
20. Primary Endpoint Analysis Framework
| Analysis component | Statistical role |
|---|---|
| Claims-based algorithm | Defines which claims patterns count as moderate or severe COPD exacerbations. |
| Event count | Provides the numerator for the annualized event rate. |
| Person-time | Provides the denominator for the rate and accounts for different observation durations. |
| Count model | Can estimate event rates while accounting for exposure time. |
| Rate ratio | Can compare annual event rates between the two intervention groups. |
| Confidence interval | Would quantify uncertainty around a reported rate ratio. |
| Hypothesis test | Could evaluate a prespecified null hypothesis about equality of event rates if specified in the statistical analysis plan. |
21. Related Clinical Trial Results
22. Sources
- ClinicalTrials.gov: NCT05062304 — IMPACT COPD.
Continue through the Clinical Biostats knowledge graph
Explore statistical tutorials, calculators, and additional clinical-trial analyses for deeper study of clinical research methods.
23. Record Summary
IMPACT COPD is a completed study titled “Replication of the IMPACT COPD Trial in Healthcare Claims Data,” with 17281 enrolled participants and two listed drug interventions: Fluticasone Furoate-Vilanterol Trifenatate and Furoate-umeclidinium-vilanterol. Its registered primary endpoint is the annual rate of moderate or severe COPD exacerbations during treatment, measured to study completion or censoring, up to 32 months.
Statistically, the central issue is the analysis of a recurrent claims-based event rate rather than a single binary outcome. Appropriate interpretation requires attention to the claims algorithm, event counting, person-time, censoring, dispersion, and the choice of rate-based statistical model. The registry does not post statistical analyses for the primary endpoint, so there are no reported treatment-effect estimates, confidence intervals, or p-values to interpret from the ClinicalTrials.gov record.